Source: FDA
Topic: FDA approves first Factor XIa inhibitor for secondary stroke prevention
The FDA has approved Sunharbo (asundexian), the first Factor XIa inhibitor, to reduce the risk of recurrent ischemic stroke in adults following a recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA). It is taken once daily alongside antiplatelet therapy.
Approval was supported by the phase 3 OCEANIC-STROKE trial involving 12,327 patients. Asundexian reduced the risk of recurrent ischemic stroke compared with placebo, without a significant increase in major bleeding overall.
Clinical significance: Factor XIa inhibition offers a new approach to preventing recurrent ischemic stroke by targeting the coagulation pathway. It may provide additional protection while maintaining a relatively low major-bleeding risk in appropriately selected patients.
Link: https://www.fda.gov/news-events/press-announcements/fda-approves-first-factor-xla-inhibitor-help-prevent-stroke-certain-adults-high-risk
@HakimApps_Guideline
